메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

EPS Corporation Selects ArisGlobal's LifeSphere® MultiVigilance

Prominent Japan CRO adopts new safety case processing system to further enhance compliance, automation, and efficiency BOSTON, Dec. 18, 2025 -- ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, today announced that EPS Corporation, a leading Japan-based contract research organization (CRO), has selected LifeSphere® MultiVigilance to modernize how it manages pharmacovigilance case processing on behalf of its sponsor partners. By implementing LifeSphere MultiVigilance, EPS will modernize its case processing inf
- 김갑성 기자
- 2025-12-18 16:27
CorestemChemon Advances Toward ALS Stem Cell Commercialization with Regulatory Progress in Korea and NSF-Backed U.S. Expansion

SEOUL, South Korea, Dec. 18, 2025 -- CorestemChemon (KOSDAQ: 166480) is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supported regenerative medicine ecosystem in the United States, secured commercialization capital, and a sizable open-market share purchase by the CEO. Key Strategic Updates Progressing through an advanced MFDS review of a precision-targeted ALS subgroup strategy in Korea Selected to participate in
- 김갑성 기자
- 2025-12-18 10:31
Alphamab Oncology Announces IND Application for Innovative PD-L1/ VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE

SUZHOU, China, Dec. 18, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a clinical study of JSKN027 for the treatment of advanced malignant solid tumors. JSKN027 is a first-in-class bispecific ADC designed to co-engage PD-L1 and VEGFR2. By leveraging glyc
- 김갑성 기자
- 2025-12-18 10:26
SynbioTech Wins 5 Gold Medals at US Innovation Awards

[ 메디채널 김갑성 기자 ] ABKEFIR® Boosts Probiotic Strength Over 50% by "Symbiotic Fermentation" KAOHSIUNG, Dec. 18, 2025 -- SynbioTech INC., ranked among the top 20 global probiotic suppliers, proudly announced a significant triumph at the 2025 AII DaVinci International Innovation and Invention Expo. The company won five Gold Medals for its pioneering probiotic and postbiotic solutions. SynbioTech's scientifically validated breakthroughs in precision health earned high acclaim from the international panel of judges. The award-winning innovations include: ABKEF
- 김갑성 기자
- 2025-12-18 09:00
Bupa Hong Kong has selected Cognizant to deliver an AI-driven BPaaS solution to transform health insurance claims

Strategic collaboration aims to enhance operational efficiency and mitigate risks by transitioning to a business process more aligned with regulatory requirements HONG KONG, Dec. 18, 2025 -- Cognizant (Nasdaq: CTSH) today announced a strategic collaboration with Bupa Hong Kong, a leading health insurance specialist in Hong Kong, to deliver Cognizant's first AI-driven Business-Process-as-a-Service (BPaaS) solution for claims modernization in the region. The five-year engagement represents the largest Intuitive Operations and Automation (IOA) services deal for Cognizant in Hong K
- 김갑성 기자
- 2025-12-18 08:00
Bupa Hong Kong has selected Cognizant to deliver an AI-driven BPaaS solution to transform health insurance claims

Strategic collaboration aims to enhance operational efficiency and mitigate risks by transitioning to a business process more aligned with regulatory requirements HONG KONG, Dec. 18, 2025 -- Cognizant (Nasdaq: CTSH) today announced a strategic collaboration with Bupa Hong Kong, a leading health insurance specialist in Hong Kong, to deliver Cognizant's first AI-driven Business-Process-as-a-Service (BPaaS) solution for claims modernization in the region. The five-year engagement represents the largest Intuitive Operations and Automation (IOA) services deal for Cognizant in Hong K
- 김갑성 기자
- 2025-12-18 08:00
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature

SAN FRANCISCO and SUZHOU, China, Dec. 18, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of two Phase 3 clinical studies of mazdutide, the world's first approved glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-1, DREAMS-2) have been published back-
- 김갑성 기자
- 2025-12-18 08:00
Nabsys and Hitachi Present Electronic Genome Mapping Data at Japanese Society of Human Genetics (JSHG) 2025 Annual Meeting

TOKYO, Dec. 18, 2025 -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, in partnership with Hitachi High-Tech Corporation (HHT) announces the presentation of high resolution structural variation data on the OhmX(™) platform at the Japanese Society of Human Genetics (JSHG) Annual Meeting taking place on December 17-20, 2025, in Yokohama, Japan. In partnership with Dr. Catherine Brownstein, M.P.H., Ph.D. from Boston Children's Hospital, Nabsys and HHT will host a luncheon seminar on Thursday, December 18, 2025 from 12:25-1:25 PM at the Yokohama Confer
- 김갑성 기자
- 2025-12-18 05:05
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets

TOKYO, Dec. 18, 2025 -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets. By combining Talus Bio's assay technologies for screening for TF and PPI inhibitors in native cellular environment with PRISM's chemistry designed to target protein-protein interactions, companies are in a unique position to discover and develop drugs against these challenging targets. Under
- 김갑성 기자
- 2025-12-18 00:00
Neutrinos Wins AI and Machine Learning Innovation Award at InsurInnovator Connect Vietnam 2025

Award recognizes Neutrinos' contribution to advancing AI adoption across the APAC region NEW YORK and SINGAPORE, Dec. 17, 2025 -- Neutrinos, a leader in AI-powered intelligent automation for insurers, has been recognized with the AI and Machine Learning Innovation Award at the IIC Vietnam Awards 2025. Held in conjunction with the annual InsurInnovator Connect Vietnam conference, the awards highlight innovations and initiatives that drive measurable progress and raise industry standards. Neutrinos received this recognition for its work in helping insurers operationalize
- 황정호 기자
- 2025-12-17 22:30

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-18_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 18일 19시 10분